

60 YEARS OF NEUROENDOCRINOLOGY

Regulation of mammalian neuroendocrine physiology and rhythms by melatonin

Jonathan D Johnston and Debra J Skene

Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey GU2 7XH, UK

Correspondence should be addressed to J D Johnston
Email
j.johnston@surrey.ac.uk

Abstract

The isolation of melatonin was first reported in 1958. Since the demonstration that pineal melatonin synthesis reflects both daily and seasonal time, melatonin has become a key element of chronobiology research. In mammals, pineal melatonin is essential for transducing day-length information into seasonal physiological responses. Due to its lipophilic nature, melatonin is able to cross the placenta and is believed to regulate multiple aspects of perinatal physiology. The endogenous daily melatonin rhythm is also likely to play a role in the maintenance of synchrony between circadian clocks throughout the adult body. Pharmacological doses of melatonin are effective in resetting circadian rhythms if taken at an appropriate time of day, and can acutely regulate factors such as body temperature and alertness, especially when taken during the day. Despite the extensive literature on melatonin physiology, some key questions remain unanswered. In particular, the amplitude of melatonin rhythms has been recently associated with diseases such as type 2 diabetes mellitus but understanding of the physiological significance of melatonin rhythm amplitude remains poorly understood.

Key Words

- ▶ pineal
- ▶ pars tuberalis
- ▶ pars distalis
- ▶ development
- ▶ reproduction
- ▶ prolactin
- ▶ thyroid
- ▶ deiodinase
- ▶ circadian rhythm
- ▶ clock gene
- ▶ amplitude

Journal of Endocrinology
(2015) 226, T187–T198

Melatonin and the photoneuroendocrine system

Overview of melatonin's discovery

The discovery of melatonin was made by Lerner *et al.* (1958), coincidentally only a few years after publication of Harris' monograph, *Neural Control of the Pituitary Gland* (Harris 1955), which is often considered to have established neuroendocrinology as a discipline and is celebrated in this special issue of the journal. Lerner was seeking to identify the molecule(s) in bovine pineal glands known to cause blanching of amphibian skin. This work

led to isolation of a factor, termed melatonin, which causes potent aggregation of melanin granules in frog melanocytes (Lerner *et al.* 1958). Shortly afterwards, the chemical structure of melatonin was revealed as N-acetyl-5-methoxytryptamine (Lerner *et al.* 1959). From its origins in a dermatology laboratory, melatonin has become a key molecule in the field of chronobiology. As described in this review, melatonin provides an extremely robust endocrine signal of both circadian time and day-length, enabling it to influence both daily and seasonal rhythms in many species. Melatonin is synthesised by multiple tissues in the body, but the pineal gland is the major

contributor to circulating melatonin concentration, as pinealectomy abolishes detectable melatonin in the blood (Lewy *et al.* 1980a).

Circadian rhythmicity of pineal melatonin synthesis

Concentrations of melatonin in the blood exhibit a pronounced circadian rhythm, with elevated levels during the biological night in all species. The primary driver of melatonin rhythmicity is the endogenous circadian system, as daily rhythms of melatonin persist in constant dim light and in the absence of rhythmic environmental cues. In most mammalian species, the circadian rhythm of pineal melatonin synthesis is due to a poly-synaptic pathway linking the pineal gland to the hypothalamic suprachiasmatic nuclei (SCN), which house the master circadian clock in mammals (Moore & Eichler 1972, Stephan & Zucker 1972). The pathway has been mapped by classical lesioning and tracer studies (reviewed in Moore (1996)), together with transneuronal retrograde tracer experiments (Larsen *et al.* 1998, Teclemariam-Mesbah *et al.* 1999). From the SCN, it passes via the paraventricular nuclei, the upper thoracic intermediolateral cell column of the spinal cord and then sympathetic neurones of the superior cervical ganglion, which innervate the pineal. This series of connections linking retina to SCN to pineal gland is sometimes referred to as a photoneuroendocrine system.

The circadian, SCN-driven sympathetic innervation of the pineal gland results in activation of arylalkylamine-N-acetyltransferase (AA-NAT), a key enzyme in the melatonin synthesis pathway (Klein 2007). Noradrenaline released by the sympathetic neurones stimulates cAMP production and AA-NAT activity in pinealocytes via both $\beta 1$ (Deguchi & Axelrod 1972, Klein & Weller 1973) and $\alpha 1$ (Klein *et al.* 1983, Vanecek *et al.* 1985) adrenoceptors. In rodents, this leads to high amplitude rhythms in pineal *Aa-nat* mRNA abundance (Borjigin *et al.* 1995, Coon *et al.* 1995) indicating that AA-NAT synthesis is a major mechanism driving the melatonin synthesis rhythm. However melatonin synthesis in all species also involves important post-translational mechanisms such as the stabilisation of AA-NAT protein by interaction with 14-3-3 proteins (Ganguly *et al.* 2001). In comparison to rodents, pineal physiology of ungulate and primate species is believed to primarily utilise post-transcriptional mechanisms, as it exhibits very little daily change in mRNA of *Aa-nat* and other genes known to be rhythmic in the rodent pineal (Coon *et al.* 1995, Privat *et al.* 1999, Johnston *et al.* 2004). Moreover stimulation of bovine pinealocytes

with noradrenaline induces AA-NAT activity without any change in *Aa-nat* mRNA expression (Schomerus *et al.* 2000). Further data describing species differences in melatonin synthesis are reviewed elsewhere (Stehle *et al.* 2001).

In addition to being an SCN-driven rhythm, the daily variation in melatonin synthesis is also in part regulated by the ambient light-dark cycle. Light is a powerful synchroniser of SCN rhythms (reviewed in Hughes *et al.* (2015)). Furthermore, exposure to light during the night acutely inhibits melatonin synthesis and secretion in both animal models (Klein & Weller 1972, Illnerova *et al.* 1979) and humans (Lewy *et al.* 1980b). The daily rhythm of melatonin concentration is thus the result of complex interplay between endogenous and exogenous factors.

Melatonin as a marker of circadian phase

The timing of the endogenous melatonin rhythm is considered the most reliable marker of SCN clock timing and is used routinely to assess circadian phase in humans. Melatonin can be measured directly in plasma and saliva samples, or indirectly as its urinary metabolite, 6-sulphatoxymelatonin (aMT6s), thus providing circadian phase information in both laboratory and non-laboratory studies (reviewed in Skene & Arendt (2006)). Compared with core body temperature and cortisol rhythms, melatonin is least affected by activity, sleep, meals and stress.

The timing of the rhythm can be measured by estimating the time of melatonin onset, peak or offset (reviewed in Skene & Arendt (2006)). The time of melatonin onset in dim light conditions, the so-called dim light melatonin onset (DLMO; Lewy & Sack 1989), has frequently been used as a marker of circadian phase, although it may be better to measure both melatonin onset and offset as there is some evidence to suggest that these may be shifted differentially (Warman *et al.* 2003). Preferably, however, the whole melatonin profile should be measured to capture both melatonin timing and amplitude. The timing of the melatonin and urinary aMT6s rhythms has provided important information of an individual's circadian phase in numerous studies of circadian desynchrony and has also been used to optimize the timing of light and melatonin in the treatment of circadian rhythm sleep-wake disorders.

Melatonin as an endocrine calendar

The 24-h melatonin signal not only represents endogenous circadian time but also encodes seasonal information.

Specifically, the duration of elevated melatonin concentration is proportional to duration of the night and thus dependent upon the prevailing photoperiod (reviewed in Reiter (1993)). This photoperiodic regulation of melatonin signal duration is a consequence of adaptation of SCN physiology. Day-length is encoded in multiple SCN rhythms, including gene expression, electrical activity and gating of sensitivity to input stimuli as reviewed elsewhere (Johnston 2005, Coomans *et al.* 2015). Altered neuronal output from the SCN then drives melatonin signal duration via the SCN-pineal poly-synaptic pathway as described above.

The ability of melatonin to provide an endocrine representation of photoperiod is an essential component of the seasonal biology of many species. Removal of the pineal gland has long been known to block the ability of photoperiod to regulate the seasonal physiology of mammals. However there was debate in the literature as to what element(s) of the melatonin signal actually carried photoperiodic information. Early studies of intact hamsters revealed an ability of melatonin injections to induce short photoperiod-like physiology, but only when given at certain times of the day (Tamarkin *et al.* 1976, 1977). Possible explanations for these data included rhythmic sensitivity to melatonin and extension of the endogenous melatonin signal duration by the injections. A series of elegant timed infusion studies conducted by multiple laboratories using pinealectomised animals later revealed that duration is likely to be the key feature of the melatonin rhythm that regulates photoperiodic changes in physiology (reviewed in Bartness *et al.* (1993)). The contrast between short duration signals in the summer and long duration winter signals is both necessary and sufficient to drive subsequent seasonal rhythms in diverse processes such as reproduction, pelage, metabolism, and immune function (Goldman 2001, Stevenson & Prendergast 2015).

Melatonin receptors

Endogenous melatonin acts through activation of membrane bound, high affinity, G-protein coupled receptors. Early studies using the radioligand 2-[¹²⁵I]iodomelatonin identified and quantified high-affinity melatonin receptors in numerous vertebrate species (Dubocovich 1995, Reppert & Weaver 1995, Vanecek 1988a). Subsequent molecular cloning identified two melatonin receptors, Mel1a (MT1) and Mel1b (MT2) in mammals (Reppert *et al.* 1994, 1995a) and an additional melatonin receptor, Mel1c, in birds (Reppert *et al.* 1995b). The MT2

receptor was cloned from humans (362 amino acids) and is 60% identical to the human MT1 receptor at the amino acid level (350 amino acids). The MT2 receptor is preferentially expressed in the human retina and selected brain regions, notably the hippocampus. The expressed recombinant MT2 receptor exhibits similar ligand binding characteristics and pharmacology to the MT1 receptor (Kd <200 pM; specificity 2-iodomelatonin > melatonin ≥ 6-chloromelatonin > N-acetylserotonin >> serotonin) and is also coupled to G_i resulting in inhibition of adenylate cyclase, cAMP concentration and downstream signal transduction pathways (Reppert 1997).

There is a high density of melatonin receptor expression in neuroendocrine tissues, including the hypothalamic SCN, pituitary pars tuberalis (PT) and developing gonadotroph cells. Melatonin receptors have also been detected elsewhere, including the adrenal gland (MT1), arteries and heart (MT1, MT2), lung (MT1, MT2), liver (MT1, MT2), kidney (MT1), small intestine (MT2), skin (MT1, MT2), and in T and B lymphocytes (MT1) (reviewed in Zawilska *et al.* (2009)). However the physiological function of melatonin is not well understood in many of these tissues. Notable examples of melatonin's regulation of endocrine function include regulation of metabolic physiology, such as insulin secretion and glucose homeostasis (Peschke 2008, Karamitri *et al.* 2013). This review, however, will focus on neuroendocrine examples, primarily via its action in the hypothalamus and pituitary gland.

Circadian actions of endogenous melatonin in adults

The MT1 receptor is strongly expressed in the SCN, which is considered a major site of melatonin action. Early studies using mice with targeted disruption of the Mel1a (MT1) receptor revealed that this receptor was necessary for the acute inhibitory action of melatonin on SCN neuronal firing (Liu *et al.* 1997). However, phase shifts by melatonin were still evident in these MT1 deficient mice (Liu *et al.* 1997). Subsequent transgenic studies (von Gall *et al.* 2002b, Jin *et al.* 2003) and pharmacological studies showing blockade of melatonin-induced phase shifts by MT2 antagonists (Dubocovich *et al.* 1998, Hunt *et al.* 2001) suggest MT2 receptor involvement in melatonin's phase shifting action.

In addition to its effects in the SCN, melatonin's robust rhythmicity in the circulation makes it an attractive candidate molecule involved in the synchronization of circadian clocks throughout the body. This issue

has been discussed in detail by others (Stehle *et al.* 2003, Pevet *et al.* 2006).

Regulation of seasonal physiology via the pituitary pars tuberalis (PT)

Aside from the SCN, the pituitary gland is the best studied melatonin target tissue. In adult mammals, the dominant pituitary site of melatonin action is the PT, a thin layer of the anterior pituitary that surrounds the pituitary stalk and extends rostrally along the ventral surface of the median eminence (reviewed in Wittkowski *et al.* (1999)). Co-localisation studies have revealed expression of MT1 receptors in thyroid stimulating hormone (TSH)-positive cells of the PT (Klosen *et al.* 2002, Dardente *et al.* 2003a). These cells are often referred to as PT-specific thyrotrophs. Despite their expression of TSH, they lack cellular components associated with the primary population of thyrotroph cells in the pars distalis of the anterior pituitary (Bockmann *et al.* 1997). It is now believed that melatonin signal duration drives the photoperiodic control over multiple aspects of neuroendocrine physiology, including the lactotrophic and reproductive axes, via the PT in adult mammals.

Photoperiodic regulation of prolactin secretion

In many seasonally breeding species, the lactotrophic axis exhibits robust annual cycles with increased prolactin secretion during the spring and summer months, irrespective of the timing of the breeding season. Compelling *in vivo* evidence for an intra-pituitary mechanism regulating photoperiodic prolactin rhythm came from the hypothalamo-pituitary disconnected (HPD) ram model. The HPD ram lacks neuronal connections between the hypothalamus and pituitary gland, but has intact pituitary vasculature (Clarke *et al.* 1983). Despite this lack of neuronal connection between hypothalamus and pituitary, alternate summer and winter photoperiods are able to drive appropriate annual cycles of plasma prolactin concentration (Lincoln & Clarke 1994).

Studies of pituitary melatonin receptor expression revealed a lack of melatonin receptors on lactotroph cells, implying an indirect mechanism of melatonin on prolactin secretion. The importance of the PT in the seasonal regulation of prolactin secretion was first demonstrated by the fact that PT-conditioned medium stimulates prolactin secretion from pituitary pars distalis cell cultures (Hazlerigg *et al.* 1996, Morgan *et al.* 1996). It was therefore postulated that the photoperiodic

melatonin signal regulates the release of a prolactin secretagogue, termed tuberlin, from the PT. Later evidence indicated that tuberlin secretion is dependent upon photoperiod (Stirland *et al.* 2001) and endogenous seasonal timing mechanisms (Johnston *et al.* 2003a, Lincoln *et al.* 2005). Despite strong evidence for the existence of tuberlin, attempts to identify it have not been successful (Lafarque *et al.* 1998, Guerra & Rodriguez 2001, Graham *et al.* 2002). More detailed reviews of this subject can be found elsewhere (Johnston 2004, Dardente 2007, Dupre 2011).

Photoperiodic regulation of reproduction

More recently, the PT has also been implicated in melatonin-driven seasonal reproductive rhythms. Based upon the results from the HPD ram (Lincoln & Clarke 1994) and lesioning studies in seasonally breeding hamsters (Maywood & Hastings 1995), 'a dual site hypothesis' was originally proposed, in which melatonin acted at the PT to regulate seasonal prolactin rhythms, but in the hypothalamus to regulate seasonal reproduction. Despite this supportive evidence, there were also data in conflict with the dual-site hypothesis. For example, some seasonally breeding species had no detectable melatonin receptors within the hypothalamus (Weaver & Reppert 1990).

Data have linked thyroid hormone physiology to seasonality in birds for many years (reviewed in Follett & Nicholls (1984)). A more recent breakthrough in the understanding of seasonal physiology also came from studies of birds, specifically the Japanese quail. This research revealed that photoperiod regulates expression of deiodinase (DIO) enzymes within the hypothalamus to drive seasonal variation in local concentration of tri-iodothyronine (T_3), the most active form of thyroid hormone (Yoshimura *et al.* 2003, Yasuo *et al.* 2005). This model has now been extended to mammals, in which it had been previously demonstrated that thyroid hormone signalling is involved in seasonal rhythms (Vriend 1985, Nicholls *et al.* 1988, Moenter *et al.* 1991, Webster *et al.* 1991). In brief, melatonin action on the PT-specific thyrotroph cells is proposed to regulate release of TSH, which then functions via a retrograde signalling pathway to regulate DIO expression in hypothalamic tanycytes that line the third ventricle (Hanon *et al.* 2008). Increased expression of DIO2 and/or reduced DIO3 in the lengthening photoperiods of spring and summer then increases conversion of thyroxine to T_3 . The mechanism to produce locally elevated T_3 concentrations in long photoperiods

appears to be the same in both long and short-photoperiod breeders (Revel *et al.* 2006, Hanon *et al.* 2008). This therefore suggests that species-specific mechanisms within the hypothalamus regulate seasonal breeding status downstream of T₃ generation. For further detail, readers are referred to recent reviews of this topic (Yoshimura 2013, Dardente *et al.* 2014, Wood & Loudon 2014).

Decoding the durational melatonin signal

Despite recent advances in determining the endocrine mechanisms through which melatonin drives seasonal physiology, the cell signalling mechanisms used to interpret melatonin signal duration are still unclear. To date, evidence suggests that melatonin duration is able to alter sensitisation of intracellular signal transduction pathways and also determine the temporal coincidence of rhythmic gene expression.

Chronic activation of receptors that are negatively coupled to adenylate cyclase (AC) can lead to sensitisation of AC signal transduction pathways (Thomas & Hoffman 1987). Indeed, pre-treatment of Chinese hamster ovary cells expressing human MT1 (Witt-Enderby *et al.* 1998), neonatal rat pituitary cells (Pelisek & Vanecek 2000) and pancreatic INS-1 β cells (Kemp *et al.* 2002) with melatonin sensitises subsequent stimulation by forskolin. However it is the PT cell model that has been most used to study sensitisation effects of melatonin, as reviewed in detail by Barrett *et al.* (2003). In the context of understanding the decoding of photoperiodic melatonin signalling, it is not sufficient to identify the presence of sensitisation *per se* in PT cells, but determine whether there are differences in sensitisation between melatonin signal durations encountered in long and short photoperiods. This experiment was performed in ovine pituitary cells that, in many temperate latitudes, would be exposed to melatonin signal duration of ~8 h in a long summer photoperiod and 16 h in a short winter photoperiod. Exposure of ovine PT cells to 16 h of melatonin increases AC sensitivity to stimulants such as forskolin (Hazlerigg *et al.* 1993) and CTX (Barrett *et al.* 2000), in addition to causing a significant increase in basal AC activity (Hazlerigg *et al.* 1993). By contrast, exposure to a melatonin signal of 8-h or less causes less sensitisation (Hazlerigg *et al.* 1993). Altered sensitisation of PT cells by physiologically encountered melatonin signals may therefore contribute to photoperiodic timing mechanisms.

Identification of clock gene expression in the PT (Sun *et al.* 1997) invited speculation that there may be circadian mechanisms within the PT involved in decoding melatonin signals. Initial studies focused on *Period1* (*Per1*), which

is known to be sensitive to cAMP-dependent signalling, and revealed a transient increase of expression immediately following the morning decline of melatonin (Morgan *et al.* 1998, von Gall *et al.* 2002a). Later work revealed rhythmic expression of mRNA for multiple clock genes in the ovine PT (Lincoln *et al.* 2002). Of note *Cryptochrome1* (*Cry1*) and *Per1* mRNAs were found to be expressed immediately following the onset and offset of the daily melatonin signal, respectively, in both long and short photoperiod (Lincoln *et al.* 2002). As formation of PER and CRY protein complexes is an important functional step in circadian transcriptional repression, it has been hypothesised that melatonin signal duration may transmit day length information via the differential formation of such protein complexes (Lincoln *et al.* 2003). The demonstration that melatonin onset *per se* induces PT expression of *Cry1* (Dardente *et al.* 2003b, Hazlerigg *et al.* 2004), made it one of the first genes reported to be acutely stimulated by melatonin. However, subsequent work revealed that melatonin onset stimulates a range of genes and transcription factor pathways (Dupre *et al.* 2008, Fustin *et al.* 2009, Unfried *et al.* 2010), indicating that a molecular coincidence model need not necessarily be dependent upon clock genes, but could conceivably include acute regulation of multiple genes and their protein products. Direct testing of the coincidence model has not yet been possible to a large degree due to the technical difficulty associated with *in vivo* genetic manipulation in photoperiodic species.

Melatonin signalling in neuroendocrine tissues during early development

Although the PT has proved to be a valuable model tissue for the study of melatonin action in adult animals, progress has been made understanding the physiological actions of melatonin elsewhere in the body at various developmental stages. Melatonin became a focus of research on maternal-foetal signalling, due to its robust circadian rhythm and its lipophilic nature, which allows it to cross the placenta (Reppert *et al.* 1979, Yellon & Longo 1987, Zemdegs *et al.* 1988) and even pass into milk (Reppert & Klein 1978, Illnerova *et al.* 1993). In addition to the following examples, evidence indicates effects of maternal melatonin on foetal and neonatal endocrine physiology outside of the scope of this review, including the regulation of adrenal gland (Torres-Farfan *et al.* 2011) and adipose tissue (Seron-Ferre *et al.* 2014) function.

Direct regulation of the pituitary pars distalis

The distribution of melatonin receptors is more widespread during embryogenesis than in adulthood, suggesting novel role(s) for melatonin in early development (Davis 1997, Seron-Ferre *et al.* 2012). Although developmental changes in melatonin receptor expression have been reported in neuroendocrine tissues such as the thyroid and nasal epithelium (Rivkees & Reppert 1991, Helliwell & Williams 1994), the pituitary gland is the best studied example.

Initial research in this area demonstrated that melatonin is able to acutely inhibit gonadotrophin-releasing hormone (GnRH)-stimulated gonadotrophin secretion from neonatal rat pituitary cells (Martin & Klein 1976). Developmental loss of melatonin sensitivity in the rat pituitary was then revealed by the gradual decline of this endocrine function over the first 2–3 weeks of postnatal life (Martin & Sattler 1979), together with a parallel postnatal loss of iodo-melatonin binding sites (Vanecek 1988b). These developmental changes and the mechanisms of melatonin signalling in gonadotroph cells are reviewed in detail elsewhere (Vanecek 1999).

Mapping of *Mt1* mRNA expression using *in situ* hybridisation histochemistry has allowed more detailed analysis of melatonin sensitivity in the developing rat pituitary. Consistent with iodo-melatonin binding studies, the onset of *Mt1* expression is at embryonic day 15 (Johnston *et al.* 2006). During embryogenesis, *Mt1* is strongly expressed in the PT (or rostral tip) region of the anterior pituitary and extends along the ventral pituitary surface, a region known to house newly differentiated gonadotroph cells (Scully & Rosenfeld 2002). Direct evidence of melatonin receptor expression in gonadotroph cells was then provided by co-localisation of *Mt1* with luteinising hormone beta (LH β) and alpha glycoprotein subunit (α GSU) mRNA in both the embryonic and neonatal rat pituitary (Johnston *et al.* 2003b, Johnston *et al.* 2006). The effects of melatonin on reproductive physiology in early development are therefore likely to be, at least in part, via a direct action on the pituitary gonadotroph cells, in contrast to the mechanisms driving photoperiodic reproduction in adults, as previously described.

Investigation of the molecular mechanisms regulating *Mt1* promoter activity has attempted to identify the mechanisms that drive down-regulation of melatonin receptor expression in developing pituitary gonadotroph cells. Sequencing of the rat *Mt1* promoter (Johnston *et al.* 2003c) and subsequent reporter assays (Johnston *et al.*

2003b) suggested the presence of a functional *cis*-element for the transcription factor EGR-1 proximal to the *Mt1* transcription start site. Expression of EGR-1 in gonadotroph cells is induced by GnRH and is a molecular component through which GnRH stimulates LH β synthesis (Dorn *et al.* 1999, Tremblay & Drouin 1999). It was therefore hypothesised that, around late embryogenesis in rodents, the onset of pulsatile GnRH secretion from the hypothalamus induces EGR-1 expression to simultaneously stimulate LH β and inhibit *Mt1* transcription. The hypothesis received support from analysis of the *hypogonadal* mouse, which is unable to synthesise GnRH and exhibits a fourfold increase in pituitary *Mt1* mRNA compared to wild type littermates (Johnston *et al.* 2003b). Further support came from *in vitro* experiments, which have shown that endogenous *Mt1* mRNA expression is up-regulated by a GnRH receptor antagonist in GT1–7 neuronal cells (Ishii *et al.* 2009) and down-regulated by a GnRH receptor agonist in the α T₃-1 gonadotroph cell line (Bae *et al.* 2014). However, recent data have also revealed that pituitary *Mt1* expression is unaltered in adult rats treated with a GnRH receptor antagonist and also in *Egr1*^{-/-} mice (Bae *et al.* 2014). It is therefore clear that further work is required to fully elucidate the mechanisms controlling melatonin sensitivity in developing gonadotroph cells.

Synchronisation of foetal circadian rhythms by maternal melatonin

Circadian clocks have been widely reported in foetal and neonatal individuals of model species (reviewed in Seron-Ferre *et al.* (2012)). Moreover, these clocks are synchronised (entrained) by maternal factors, during the early stages of development before the SCN receive neuronal innervation from the retina (Stanfield & Cowan 1976, Mason *et al.* 1977).

Much of the evidence for maternal melatonin in perinatal circadian entrainment has derived from studies of the Syrian hamster, which possesses more melatonin receptors in the SCN of foetal and neonate animals than adults (Duncan & Davis 1993, Gauer *et al.* 1998). Whereas behavioural rhythms of adult hamsters appear insensitive to melatonin (Hastings *et al.* 1992), neonate hamsters are readily entrained to melatonin injections (Grosse *et al.* 1996). Remarkably, injection of pregnant mothers entrains rhythms of foetal pups, demonstrating the effect of melatonin and its ability to cross the placenta (Davis & Mannion 1988). Evidence for the role of SCN melatonin receptors in this process comes from elegant

transplantation studies. Lesioning of the SCN in adult hamsters renders them arrhythmic, but transplantation of foetal SCN tissue restores behavioural rhythms that can be entrained by melatonin (Grosse & Davis 1998).

Pharmacological uses of melatonin

Chronobiotic effects

The ability of exogenously administered melatonin to phase shift human circadian rhythms was described in the 1980s (Arendt *et al.* 1985). If given (0.5–10 mg p.o.) before the natural rise of endogenous melatonin, phase advances in sleep, core body temperature, melatonin and prolactin have been observed (Deacon & Arendt 1995, Krauchi *et al.* 1997, Rajaratnam *et al.* 2003). By contrast, melatonin administered in the early biological morning (i.e. 1–4 h after the core body temperature nadir) can produce phase delays in circadian timing. This ability of melatonin to advance or delay clock timing depending on the biological time of administration has been described in terms of a phase response curve (PRC) (Lewy *et al.* 1992, Middleton *et al.* 1997, Revell & Eastman 2005, Burgess *et al.* 2008). The magnitude of the phase shift is dose-dependent (Deacon & Arendt 1995, Burgess *et al.* 2010).

The phase shifting effects of melatonin have been utilised in the treatment of circadian rhythm sleep–wake disorders in which the sleep/wake cycle is desynchronised from the circadian timing system, reviewed in Arendt & Skene (2005). Appropriately timed melatonin has been shown to alleviate symptoms of jet lag and night shift work. Melatonin is also the treatment of choice for non-24-h sleep–wake disorder suffered by totally blind people with no conscious light perception (Skene & Arendt 2007). In this condition, melatonin entrains the free-running non-24-h circadian rhythms including the sleep–wake cycle leading to increased night sleep duration and a reduction in the number and duration of daytime naps. Melatonin (0.3–5 mg p.o.) has also been used in the treatment of delayed sleep–wake phase disorder (DSPD), with dosing in the early biological evening (5–6.5 h before DLMO) proving most effective (Nagtegaal *et al.* 1998, Munday *et al.* 2005), presumably since this maximises melatonin's phase advancing effect according to the published melatonin PRCs.

A great deal of effort has focused on trying to optimise melatonin's phase shifting effect by investigating the best time of administration (biological time and clock time), the lowest effective dose, the optimal treatment regimen (duration), frequency of dosing (set or staggered) and type

of formulation (fast or slow release) (reviewed in Arendt *et al.* (2008)). More research is still needed so that these parameters are optimised for each circadian rhythm sleep–wake disorder.

Acute pharmacological effects

Exogenous melatonin causes an immediate drop in core body temperature, reduced alertness and increased tiredness (Deacon *et al.* 1994). Studies suggest that these acute effects are more pronounced if melatonin is given during the day when endogenous melatonin production is low/undetectable (Dollins *et al.* 1994). Transient sleepiness produced following melatonin ingestion before bedtime most likely accounts for the reduced sleep latency reported in several studies (Zhdanova *et al.* 1996, Lemoine *et al.* 2007). The effect of melatonin on polysomnographic sleep is less consistent with studies showing conflicting results (reviewed in Turek & Gillette (2004)).

Melatonin agonists

The similarity in pharmacology between the MT1 and MT2 receptors has hampered the identification of selective agonists to MT1 or MT2. Current melatonin agonists being developed have high affinity at both the MT1 and MT2 receptors, e.g. agomelatine (S20098, Servier), ramelteon (TAK-375, Takeda), LY156735 (Eli Lilly), tasimelteon (VEC-162, Bristol-Myers Squibb Co, licensed to Vanda). For reviews of these melatonin agonists the reader is referred to (Turek & Gillette 2004, Zawilska *et al.* 2009). These melatonin agonists are in various stages of development and drug registration. Unfortunately it is unclear how the efficacy of these novel agonists compare directly with melatonin in clinical trials since head to head comparison with melatonin is not a prerequisite for drug registration.

Perspective/future areas of research

This review has primarily dealt with the generation and function of physiological rhythms of pineal melatonin synthesis, which results in the rhythms of melatonin in the blood. Whereas the timing of the endogenous melatonin rhythm has been a major focus of the published literature, what determines the amplitude of the melatonin rhythm is less well studied. Melatonin amplitude, whilst consistent within an individual, is highly variable between individuals, declines with age and is acutely suppressed by light at night, as previously described.

Our recent research has shown reduced melatonin amplitude in type 2 diabetes mellitus compared with age and weight matched controls (Mantele *et al.* 2012), consistent with epidemiological data inversely associating melatonin concentration with insulin signalling (McMullan *et al.* 2013) and a broader literature linking melatonin signalling with glucose homeostasis (Peschke 2008, Karamitri *et al.* 2013). In this and other scenarios, understanding the physiological relevance of melatonin rhythm amplitude therefore warrants further investigation and may provide novel insights into the physiological roles of melatonin.

One powerful novel tool to understand the mechanisms underlying links between melatonin, circadian rhythms, sleep and metabolism is metabolic profiling, or metabolomics. We are currently using liquid chromatography mass spectrometry to characterise 24-h metabolite rhythms and the effect of sleep and sleep deprivation on the human metabolome (Ang *et al.* 2012, Davies *et al.* 2014). This will help to better understand melatonin, circadian timing, sleep–wake regulation and associated physiological pathways.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

The authors' recent work related to the topic of this review was supported by the Biotechnology and Biological Sciences Research Council (grant numbers BB/F020309/1 and BB/I019405/1). D J S is a Royal Society Wolfson Research Merit Award holder.

Acknowledgements

The authors wish to acknowledge the long-term mentorship of many colleagues, in particular Josephine Arendt, Professor Emeritus (University of Surrey, 1977 – present). Josephine Arendt was a pioneer in the study of melatonin in human health and disease and has been instrumental in establishing chronobiology research at the University of Surrey.

References

- Ang JE, Revell V, Mann A, Mantele S, Otway DT, Johnston JD, Thumser AE, Skene DJ & Raynaud F 2012 Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. *Chronobiology International* **29** 868–881. (doi:10.3109/07420528.2012.699122)
- Arendt J & Skene DJ 2005 Melatonin as a chronobiotic. *Sleep Medicine Reviews* **9** 25–39. (doi:10.1016/j.smrv.2004.05.002)
- Arendt J, Bojkowski C, Folkard S, Franey C, Marks V, Minors D, Waterhouse J, Wever RA, Wildgruber C & Wright J 1985 Some effects of melatonin and the control of its secretion in humans. *Ciba Foundation Symposium* **117** 266–283.

- Arendt J, Van Someren EJ, Appleton R, Skene DJ & Akerstedt T 2008 Clinical update: melatonin and sleep disorders. *Clinical Medicine* **8** 381–383. (doi:10.7861/clinmedicine.8.4-381)
- Bae SE, Wright IK, Wyse C, Samson-Desvignes N, Le Blanc P, Laroche S, Hazlerigg DG & Johnston JD 2014 Regulation of pituitary MT1 melatonin receptor expression by gonadotrophin-releasing hormone (GnRH) and early growth response factor-1 (Egr-1): *in vivo* and *in vitro* studies. *PLoS ONE* **9** e90056. (doi:10.1371/journal.pone.0090056)
- Barrett P, Choi WS, Morris M & Morgan P 2000 A role for tyrosine phosphorylation in the regulation and sensitization of adenylate cyclase by melatonin. *FASEB Journal* **14** 1619–1628. (doi:10.1096/fj.14.11.1619)
- Barrett P, Schuster C, Mercer J & Morgan PJ 2003 Sensitization: a mechanism for melatonin action in the pars tuberalis. *Journal of Neuroendocrinology* **15** 415–421. (doi:10.1046/j.1365-2826.2003.00988.x)
- Bartness TJ, Powers JB, Hastings MH, Bittman EL & Goldman BD 1993 The timed infusion paradigm for melatonin delivery: what has it taught us about the melatonin signal, its reception, and the photoperiodic control of seasonal responses? *Journal of Pineal Research* **15** 161–190. (doi:10.1111/j.1600-079X.1993.tb00903.x)
- Bockmann J, Bockers TM, Winter C, Wittkowski W, Winterhoff H, Deufel T & Kreutz MR 1997 Thyrotropin expression in hypophyseal pars tuberalis-specific cells is 3,5,3'-triiodothyronine, thyrotropin-releasing hormone, and pit-1 independent. *Endocrinology* **138** 1019–1028.
- Borjigin J, Wang MM & Snyder SH 1995 Diurnal variation in mRNA encoding serotonin N-acetyltransferase in pineal gland. *Nature* **378** 783–785. (doi:10.1038/378783a0)
- Burgess HJ, Revell VL & Eastman CI 2008 A three pulse phase response curve to three milligrams of melatonin in humans. *Journal of Physiology* **586** 639–647. (doi:10.1113/jphysiol.2007.143180)
- Burgess HJ, Revell VL, Molina TA & Eastman CI 2010 Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. *Journal of Clinical Endocrinology and Metabolism* **95** 3325–3331. (doi:10.1210/jc.2009-2590)
- Clarke IJ, Cummins JT & de Kretser DM 1983 Pituitary gland function after disconnection from direct hypothalamic influences in the sheep. *Neuroendocrinology* **36** 376–384. (doi:10.1159/000123484)
- Coomans CP, Ramkisoensing A & Meijer JH 2015 The suprachiasmatic nuclei as a seasonal clock. *Frontiers in Neuroendocrinology* **37** 29–42. (doi:10.1016/j.yfrne.2014.11.002)
- Coon SL, Roseboom PH, Baler R, Weller JL, Namboodiri MA, Koonin EV & Klein DC 1995 Pineal serotonin N-acetyltransferase: expression cloning and molecular analysis. *Science* **270** 1681–1683. (doi:10.1126/science.270.5242.1681)
- Dardente H 2007 Does a melatonin-dependent circadian oscillator in the pars tuberalis drive prolactin seasonal rhythmicity? *Journal of Neuroendocrinology* **19** 657–666. (doi:10.1111/j.1365-2826.2007.01564.x)
- Dardente H, Klosin P, Pevet P & Masson-Pevet M 2003a MT1 melatonin receptor mRNA expressing cells in the pars tuberalis of the European hamster: effect of photoperiod. *Journal of Neuroendocrinology* **15** 778–786. (doi:10.1046/j.1365-2826.2003.01060.x)
- Dardente H, Menet JS, Poirrel VJ, Streicher D, Gauer F, Vivien-Roels B, Klosin P, Pevet P & Masson-Pevet M 2003b Melatonin induces Cry1 expression in the pars tuberalis of the rat. *Brain Research. Molecular Brain Research* **114** 101–106. (doi:10.1016/S0169-328X(03)00134-7)
- Dardente H, Hazlerigg DG & Ebling FJ 2014 Thyroid hormone and seasonal rhythmicity. *Frontiers in Endocrinology* **5** 19. (doi:10.3389/fendo.2014.00019)
- Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M *et al.* 2014 Effect of sleep deprivation on the human metabolome. *PNAS* **111** 10761–10766. (doi:10.1073/pnas.1402663111)
- Davis FC 1997 Melatonin: role in development. *Journal of Biological Rhythms* **12** 498–508. (doi:10.1177/074873049701200603)

- Davis FC & Mannon J 1988 Entrainment of hamster pup circadian rhythms by prenatal melatonin injections to the mother. *American Journal of Physiology* **255** R439–R448.
- Deacon S & Arendt J 1995 Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. *Brain Research* **688** 77–85. (doi:10.1016/0006-8993(95)96872-1)
- Deacon S, English J & Arendt J 1994 Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. *Neuroscience Letters* **178** 32–34. (doi:10.1016/0304-3940(94)90282-8)
- Deguchi T & Axelrod J 1972 Control of circadian change of serotonin N-acetyltransferase activity in the pineal organ by the β -adrenergic receptor. *PNAS* **69** 2547–2550. (doi:10.1073/pnas.69.9.2547)
- Dollins AB, Zhdanova Wurtm IV, an RJ, Lynch HJ & Deng MH 1994 Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. *PNAS* **91** 1824–1828. (doi:10.1073/pnas.91.5.1824)
- Dorn C, Ou Q, Svaren J, Crawford PA & Sadovsky Y 1999 Activation of luteinizing hormone β gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. *Journal of Biological Chemistry* **274** 13870–13876. (doi:10.1074/jbc.274.20.13870)
- Dubocovich ML 1995 Melatonin receptors: are there multiple subtypes? *Trends in Pharmacological Sciences* **16** 50–56. (doi:10.1016/S0165-6147(00)88978-6)
- Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S & Masana MI 1998 Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. *FASEB Journal* **12** 1211–1220.
- Duncan MJ & Davis FC 1993 Developmental appearance and age related changes in specific 2-[125I]iodomelatonin binding sites in the suprachiasmatic nuclei of female Syrian hamsters. *Brain Research. Developmental Brain Research* **73** 205–212. (doi:10.1016/0165-3806(93)90140-6)
- Dupre SM 2011 Encoding and decoding photoperiod in the mammalian pars tuberalis. *Neuroendocrinology* **94** 101–112. (doi:10.1159/000328971)
- Dupre SM, Burt DW, Talbot R, Downing A, Mouzaki D, Waddington D, Malpoux B, Davis JR, Lincoln GA & Loudon AS 2008 Identification of melatonin-regulated genes in the ovine pituitary pars tuberalis, a target site for seasonal hormone control. *Endocrinology* **149** 5527–5539. (doi:10.1210/en.2008-0834)
- Follett BK & Nicholls TJ 1984 Photorefractoriness in Japanese quail: possible involvement of the thyroid gland. *Journal of Experimental Zoology* **232** 573–580. (doi:10.1002/jez.1402320325)
- Fustin JM, Dardente H, Wagner GC, Carter DA, Johnston JD, Lincoln GA & Hazlerigg DG 2009 Egr1 involvement in evening gene regulation by melatonin. *FASEB Journal* **23** 764–773. (doi:10.1096/fj.08-121467)
- von Gall C, Garabette ML, Kell CA, Frenzel S, Dehghani F, Schumm-Draeger PM, Weaver DR, Korf HW, Hastings MH & Stehle JH 2002a Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. *Nature Neuroscience* **5** 234–238. (doi:10.1038/nn806)
- von Gall C, Stehle JH & Weaver DR 2002b Mammalian melatonin receptors: molecular biology and signal transduction. *Cell and Tissue Research* **309** 151–162. (doi:10.1007/s00441-002-0581-4)
- Ganguly S, Gastel JA, Weller JL, Schwartz C, Jaffe H, Namboodiri MA, Coon SL, Hickman AB, Rollag M, Obsl T *et al.* 2001 Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. *PNAS* **98** 8083–8088. (doi:10.1073/pnas.141118798)
- Gauer F, Schuster C, Poirel VJ, Pevet P & Masson-Pevet M 1998 Cloning experiments and developmental expression of both melatonin receptor Mel1A mRNA and melatonin binding sites in the Syrian hamster suprachiasmatic nuclei. *Brain Research. Molecular Brain Research* **60** 193–202. (doi:10.1016/S0169-328X(98)00177-6)
- Goldman BD 2001 Mammalian photoperiodic system: formal properties and neuroendocrine mechanisms of photoperiodic time measurement. *Journal of Biological Rhythms* **16** 283–301. (doi:10.1177/074873001129001980)
- Graham ES, Webster CA, Hazlerigg DG & Morgan PJ 2002 Evidence for the biosynthesis of a prolactin-releasing factor from the ovine pars tuberalis, which is distinct from thyrotropin-releasing hormone. *Journal of Neuroendocrinology* **14** 945–954. (doi:10.1046/j.1365-2826.2002.00848.x)
- Grosse J & Davis FC 1998 Melatonin entrains the restored circadian activity rhythms of syrian hamsters bearing fetal suprachiasmatic nucleus grafts. *Journal of Neuroscience* **18** 8032–8037.
- Grosse J, Velickovic A & Davis FC 1996 Entrainment of Syrian hamster circadian activity rhythms by neonatal melatonin injections. *American Journal of Physiology* **270** R533–R540.
- Guerra M & Rodriguez EM 2001 Identification, cellular and subcellular distribution of 21 and 72 kDa proteins (tuberalins?) secreted by specific cells of the pars tuberalis *Journal of Endocrinology* **168** 363–379. (doi:10.1677/joe.0.1680363)
- Hanon EA, Lincoln GA, Fustin JM, Dardente H, Masson-Pevet M, Morgan PJ & Hazlerigg DG 2008 Ancestral TSH mechanism signals summer in a photoperiodic mammal. *Current Biology* **18** 1147–1152. (doi:10.1016/j.cub.2008.06.076)
- Harris GW 1955 *Neural Control of the Pituitary Gland*. London: Edward Arnold.
- Hastings MH, Mead SM, Vindlacheruvu RR, Ebling FJ, Maywood ES & Grosse J 1992 Non-photoc phase shifting of the circadian activity rhythm of Syrian hamsters: the relative potency of arousal and melatonin. *Brain Research* **591** 20–26. (doi:10.1016/0006-8993(92)90973-D)
- Hazlerigg DG, Gonzalez-Brito A, Lawson W, Hastings MH & Morgan PJ 1993 Prolonged exposure to melatonin leads to time-dependent sensitization of adenylate cyclase and down-regulates melatonin receptors in pars tuberalis cells from ovine pituitary. *Endocrinology* **132** 285–292.
- Hazlerigg DG, Hastings MH & Morgan PJ 1996 Production of a prolactin releasing factor by the ovine pars tuberalis. *Journal of Neuroendocrinology* **8** 489–492. (doi:10.1046/j.1365-2826.1996.04971.x)
- Hazlerigg DG, Andersson H, Johnston JD & Lincoln G 2004 Molecular characterization of the long-day response in the Soay sheep, a seasonal mammal. *Current Biology* **14** 334–339. (doi:10.1016/j.cub.2004.01.057)
- Helliwell RJ & Williams LM 1994 The development of melatonin-binding sites in the ovine fetus. *Journal of Endocrinology* **142** 475–484. (doi:10.1677/joe.0.1420475)
- Hughes S, Jagannath A, Hankins MW, Foster RG & Peirson SN 2015 Photic regulation of clock systems. *Methods in Enzymology* **552** 125–143.
- Hunt AE, Al-Ghoul WM, Gillette MU & Dubocovich ML 2001 Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. *American Journal of Physiology. Cell Physiology* **280** C110–C118.
- Illnerova H, Vanecek J, Krecek J, Wetterberg L & Saaf J 1979 Effect of one minute exposure to light at night on rat pineal serotonin N-acetyltransferase and melatonin. *Journal of Neurochemistry* **32** 673–675. (doi:10.1111/j.1471-4159.1979.tb00407.x)
- Illnerova H, Buresova M & Presl J 1993 Melatonin rhythm in human milk. *Journal of Clinical Endocrinology and Metabolism* **77** 838–841.
- Ishii H, Sato S, Yin C, Sakuma Y & Kato M 2009 Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7. *Neuroendocrinology* **90** 251–259. (doi:10.1159/000231993)
- Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM & Weaver DR 2003 Targeted disruption of the mouse Mel(1b) melatonin receptor. *Molecular and Cellular Biology* **23** 1054–1060. (doi:10.1128/MCB.23.3.1054-1060.2003)

- Johnston JD 2004 Photoperiodic regulation of prolactin secretion: changes in intra-pituitary signalling and lactotroph heterogeneity. *Journal of Endocrinology* **180** 351–356. (doi:10.1677/joe.0.1800351)
- Johnston JD 2005 Measuring seasonal time within the circadian system: regulation of the suprachiasmatic nuclei by photoperiod. *Journal of Neuroendocrinology* **17** 459–465. (doi:10.1111/j.1365-2826.2005.01326.x)
- Johnston JD, Cagampang FR, Stirling JA, Carr AJ, White MR, Davis JR & Loudon AS 2003a Evidence for an endogenous per1- and ICER-independent seasonal timer in the hamster pituitary gland. *FASEB Journal* **17** 810–815. (doi:10.1096/fj.02-0837com)
- Johnston JD, Messenger S, Ebling FJ, Williams LM, Barrett P & Hazlerigg DG 2003b Gonadotrophin-releasing hormone drives melatonin receptor down-regulation in the developing pituitary gland. *PNAS* **100** 2831–2835. (doi:10.1073/pnas.0436184100)
- Johnston JD, Messenger S, Barrett P & Hazlerigg DG 2003c Melatonin action in the pituitary: neuroendocrine synchronizer and developmental modulator? *Journal of Neuroendocrinology* **15** 405–408. (doi:10.1046/j.1365-2826.2003.00972.x)
- Johnston JD, Bashforth R, Diack A, Andersson H, Lincoln GA & Hazlerigg DG 2004 Rhythmic melatonin secretion does not correlate with the expression of arylalkylamine N-acetyltransferase, inducible cyclic amp early repressor, period1 or cryptochrome1 mRNA in the sheep pineal. *Neuroscience* **124** 789–795. (doi:10.1016/j.neuroscience.2004.01.011)
- Johnston JD, Klosen P, Barrett P & Hazlerigg DG 2006 Regulation of MT melatonin receptor expression in the foetal rat pituitary. *Journal of Neuroendocrinology* **18** 50–56. (doi:10.1111/j.1365-2826.2005.01389.x)
- Karamitri A, Renault N, Clement N, Guillaume JL & Jockers R 2013 Minireview: toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. *Molecular Endocrinology* **27** 1217–1233. (doi:10.1210/me.2013-1101)
- Kemp DM, Ubeda M & Habener JF 2002 Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. *Molecular and Cellular Endocrinology* **191** 157–166. (doi:10.1016/S0303-7207(02)00064-3)
- Klein DC 2007 Arylalkylamine N-acetyltransferase: "the Timezyme". *Journal of Biological Chemistry* **282** 4233–4237. (doi:10.1074/jbc.R600036200)
- Klein DC & Weller JL 1972 Rapid light-induced decrease in pineal serotonin N-acetyltransferase activity. *Science* **177** 532–533. (doi:10.1126/science.177.4048.532)
- Klein D & Weller JL 1973 Adrenergic-adenosine 3',5'-monophosphate regulation of serotonin N-acetyltransferase activity and the temporal relationship of serotonin N-acetyltransferase activity synthesis of 3H-N-acetylserotonin and 3H-melatonin in the cultured rat pineal gland. *Journal of Pharmacology and Experimental Therapeutics* **186** 516–527.
- Klein DC, Sugden D & Weller JL 1983 Postsynaptic α -adrenergic receptors potentiate the β -adrenergic stimulation of pineal serotonin N-acetyltransferase. *PNAS* **80** 599–603. (doi:10.1073/pnas.80.2.599)
- Klosen P, Bienvenu C, Demarteau O, Dardente H, Guerrero H, Pevet P & Masson-Pevet M 2002 The mt1 melatonin receptor and ROR β receptor are co-localized in specific TSH-immunoreactive cells in the pars tuberalis of the rat pituitary. *Journal of Histochemistry and Cytochemistry* **50** 1647–1657. (doi:10.1177/002215540205001209)
- Krauchi K, Cajochen C, Mori D, Graw P & Wirz-Justice A 1997 Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. *American Journal of Physiology* **272** R1178–R1188.
- Lafarque M, Oliveros L & Aguado L 1998 Effect of adenohipophyseal pars tuberalis secretions on pars distalis prolactin liberation. *Medicina* **58** 36–40.
- Larsen PJ, Enquist LW & Card JP 1998 Characterization of the multi-synaptic neuronal control of the rat pineal gland using viral transneuronal tracing. *European Journal of Neuroscience* **10** 128–145. (doi:10.1046/j.1460-9568.1998.00003.x)
- Lemoine P, Nir T, Laudon M & Zisapel N 2007 Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. *Journal of Sleep Research* **16** 372–380. (doi:10.1111/j.1365-2869.2007.00613.x)
- Lerner AB, Case JD, Takahashi Y, Lee TH & Mori W 1958 Isolation of melatonin, the pineal gland factor that lightens melanocytes. *Journal of the American Chemical Society* **80** 2587. (doi:10.1021/ja01543a060)
- Lerner AB, Case JD & Heinzelman RV 1959 Structure of melatonin. *Journal of the American Chemical Society* **81** 6084–6085. (doi:10.1021/ja01531a060)
- Lewy AJ & Sack RL 1989 The dim light melatonin onset as a marker for circadian phase position. *Chronobiology International* **6** 93–102. (doi:10.3109/07420528909059144)
- Lewy AJ, Tetsuo M, Markey SP, Goodwin FK & Kopin IJ 1980a Pinelectomy abolishes plasma melatonin in the rat. *Journal of Clinical Endocrinology and Metabolism* **50** 204–205. (doi:10.1210/jcem-50-1-204)
- Lewy AJ, Wehr TA, Goodwin FK, Newsome DA & Markey SP 1980b Light suppresses melatonin secretion in humans. *Science* **210** 1267–1269. (doi:10.1126/science.7434030)
- Lewy AJ, Ahmed S, Jackson JM & Sack RL 1992 Melatonin shifts human circadian rhythms according to a phase-response curve. *Chronobiology International* **9** 380–392. (doi:10.3109/07420529209064550)
- Lincoln GA & Clarke IJ 1994 Photoperiodically-induced cycles in the secretion of prolactin in hypothalamo-pituitary disconnected rams: evidence for translation of the melatonin signal in the pituitary gland. *Journal of Neuroendocrinology* **6** 251–260. (doi:10.1111/j.1365-2826.1994.tb00580.x)
- Lincoln G, Messenger S, Andersson H & Hazlerigg D 2002 Temporal expression of seven clock genes in the suprachiasmatic nucleus and the pars tuberalis of the sheep: evidence for an internal coincidence timer. *PNAS* **99** 13890–13895. (doi:10.1073/pnas.212517599)
- Lincoln GA, Andersson H & Hazlerigg D 2003 Clock genes and the long-term regulation of prolactin secretion: evidence for a photoperiod/circannual timer in the pars tuberalis. *Journal of Neuroendocrinology* **15** 390–397. (doi:10.1046/j.1365-2826.2003.00990.x)
- Lincoln GA, Johnston JD, Andersson H, Wagner G & Hazlerigg DG 2005 Photorefractoriness in mammals: dissociating a seasonal timer from the circadian-based photoperiod response. *Endocrinology* **146** 3782–3790. (doi:10.1210/en.2005-0132)
- Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK & Reppert SM 1997 Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. *Neuron* **19** 91–102. (doi:10.1016/S0896-6273(00)80350-5)
- Mantele S, Otway DT, Middleton B, Bretschneider S, Wright J, Robertson MD, Skene DJ & Johnston JD 2012 Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. *PLoS ONE* **7** e37123. (doi:10.1371/journal.pone.0037123)
- Martin JE & Klein DC 1976 Melatonin inhibition of the neonatal pituitary response to luteinizing hormone-releasing factor. *Science* **191** 301–302. (doi:10.1126/science.1108199)
- Martin JE & Sattler C 1979 Developmental loss of the acute inhibitory effect of melatonin on the *in vitro* pituitary luteinizing hormone and follicle-stimulating hormone responses to luteinizing hormone-releasing hormone. *Endocrinology* **105** 1007–1012. (doi:10.1210/endo-105-4-1007)
- Mason CA, Sparrow N & Lincoln DW 1977 Structural features of the retinohypothalamic projection in the rat during normal development. *Brain Research* **132** 141–148. (doi:10.1016/0006-8993(77)90711-9)
- Maywood ES & Hastings MH 1995 Lesions of the iodomelatonin-binding sites of the mediobasal hypothalamus spare the lactotropic, but block the gonadotropic response of male Syrian hamsters to short photoperiod and to melatonin. *Endocrinology* **136** 144–153.

- McMullan CJ, Curhan GC, Schernhammer ES & Forman JP 2013 Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women. *American Journal of Epidemiology* **178** 231–238. (doi:10.1093/aje/kws470)
- Middleton B, Arendt J & Stone BM 1997 Complex effects of melatonin on human circadian rhythms in constant dim light. *Journal of Biological Rhythms* **12** 467–477.
- Moenter SM, Woodfill CJ & Karsch FJ 1991 Role of the thyroid gland in seasonal reproduction: thyroidectomy blocks seasonal suppression of reproductive neuroendocrine activity in ewes. *Endocrinology* **128** 1337–1344. (doi:10.1210/endo-128-3-1337)
- Moore RY 1996 Neural control of the pineal gland. *Behavioural Brain Research* **73** 125–130. (doi:10.1016/0166-4328(96)00083-6)
- Moore RY & Eichler VB 1972 Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. *Brain Research* **42** 201–206. (doi:10.1016/0006-8993(72)90054-6)
- Morgan PJ, Webster CA, Mercer JG, Ross AW, Hazlerigg DG, MacLean A & Barrett P 1996 The ovine pars tuberalis secretes a factor(s) that regulates gene expression in both lactotropic and nonlactotropic pituitary cells. *Endocrinology* **137** 4018–4026.
- Morgan PJ, Ross AW, Graham ES, Adam C, Messenger S & Barrett P 1998 *oPer1* is an early response gene under photoperiodic regulation in the ovine pars tuberalis. *Journal of Neuroendocrinology* **10** 319–323. (doi:10.1046/j.1365-2826.1998.00232.x)
- Munday K, Benloucif S, Harsanyi K, Dubocovich ML & Zee PC 2005 Phase-dependent treatment of delayed sleep phase syndrome with melatonin. *Sleep* **28** 1271–1278.
- Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC & Van Der Meer YG 1998 Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. *Journal of Sleep Research* **7** 135–143. (doi:10.1046/j.1365-2869.1998.00102.x)
- Nicholls TJ, Follett BK, Goldsmith AR & Pearson H 1988 Possible homologies between photorefractoriness in sheep and birds: the effect of thyroidectomy on the length of the ewe's breeding season. *Reproduction, Nutrition, Development* **28** 375–385. (doi:10.1051/rnd:19880304)
- Pelisek V & Vanecek J 2000 Different effects of melatonin pretreatment on cAMP and LH responses of the neonatal rat pituitary cells. *Journal of Pineal Research* **28** 234–241. (doi:10.1034/j.1600-079X.2000.280406.x)
- Peschke E 2008 Melatonin, endocrine pancreas and diabetes. *Journal of Pineal Research* **44** 26–40.
- Pevet P, Agez L, Bothorel B, Saboureaux M, Gauer F, Laurent V & Masson-Pevet M 2006 Melatonin in the multi-oscillatory mammalian circadian world. *Chronobiology International* **23** 39–51. (doi:10.1080/07420520500482074)
- Privat K, Ravault JP, Chesneau D & Fevre-Montange M 1999 Day/night variation of tryptophan hydroxylase and serotonin N-acetyltransferase mRNA levels in the ovine pineal gland and retina. *Journal of Pineal Research* **26** 193–203. (doi:10.1111/j.1600-079X.1999.tb00584.x)
- Rajaratnam SM, Dijk DJ, Middleton B, Stone BM & Arendt J 2003 Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. *Journal of Clinical Endocrinology and Metabolism* **88** 4303–4309. (doi:10.1210/jc.2003-030460)
- Reiter RJ 1993 The melatonin rhythm: both a clock and a calendar. *Experientia* **49** 654–664. (doi:10.1007/BF01923947)
- Reppert SM 1997 Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. *Journal of Biological Rhythms* **12** 528–531. (doi:10.1177/074873049701200606)
- Reppert SM & Klein DC 1978 Transport of maternal[3H]melatonin to suckling rats and the fate of [3H]melatonin in the neonatal rat. *Endocrinology* **102** 582–588. (doi:10.1210/endo-102-2-582)
- Reppert SM & Weaver DR 1995 Melatonin madness. *Cell* **83** 1059–1062. (doi:10.1016/0092-8674(95)90131-0)
- Reppert SM, Chez RA, Anderson A & Klein DC 1979 Maternal-fetal transfer of melatonin in the non-human primate. *Pediatric Research* **13** 788–791. (doi:10.1203/00006450-197906000-00015)
- Reppert SM, Weaver DR & Ebisawa T 1994 Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. *Neuron* **13** 1177–1185. (doi:10.1016/0896-6273(94)90055-8)
- Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA & Gusella JF 1995a Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. *PNAS* **92** 8734–8738. (doi:10.1073/pnas.92.19.8734)
- Reppert SM, Weaver DR, Cassone VM, Godson C & Kolakowski LF Jr 1995b Melatonin receptors are for the birds: molecular analysis of two receptor subtypes differentially expressed in chick brain. *Neuron* **15** 1003–1015. (doi:10.1016/0896-6273(95)90090-X)
- Revel FG, Saboureaux M, Pevet P, Mikkelsen JD & Simonneaux V 2006 Melatonin regulates type 2 deiodinase gene expression in the Syrian hamster. *Endocrinology* **147** 4680–4687. (doi:10.1210/en.2006-0606)
- Revell VL & Eastman CI 2005 How to trick mother nature into letting you fly around or stay up all night. *Journal of Biological Rhythms* **20** 353–365. (doi:10.1177/0748730405277233)
- Rivkees SA & Reppert SM 1991 Appearance of melatonin receptors during embryonic life in Siberian hamsters (*Phodopus sungorus*). *Brain Research* **568** 345–349. (doi:10.1016/0006-8993(91)91424-Y)
- Schomerus C, Korf HW, Laedtke E, Weller JL & Klein DC 2000 Selective adrenergic/cyclic AMP-dependent switch-off of proteasomal proteolysis alone switches on neural signal transduction: an example from the pineal gland. *Journal of Neurochemistry* **75** 2123–2132. (doi:10.1046/j.1471-4159.2000.0752123.x)
- Scully KM & Rosenfeld MG 2002 Pituitary development: regulatory codes in mammalian organogenesis. *Science* **295** 2231–2235. (doi:10.1126/science.1062736)
- Seron-Ferre M, Mendez N, Abarzua-Catalan L, Vilches N, Valenzuela FJ, Reynolds HE, Llanos AJ, Rojas A, Valenzuela GJ & Torres-Farfan C 2012 Circadian rhythms in the fetus. *Molecular and Cellular Endocrinology* **349** 68–75. (doi:10.1016/j.mce.2011.07.039)
- Seron-Ferre M, Reynolds H, Mendez NA, Mondaca M, Valenzuela F, Ebensperger R, Valenzuela GJ, Herrera EA, Llanos AJ & Torres-Farfan C 2014 Impact of maternal melatonin suppression on amount and functionality of brown adipose tissue (BAT) in the newborn sheep. *Frontiers in Endocrinology* **5** 232.
- Skene DJ & Arendt J 2006 Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. *Annals of Clinical Biochemistry* **43** 344–353. (doi:10.1258/000456306778520142)
- Skene DJ & Arendt J 2007 Circadian rhythm sleep disorders in the blind and their treatment with melatonin. *Sleep Medicine* **8** 651–655. (doi:10.1016/j.sleep.2006.11.013)
- Stanfield B & Cowan WM 1976 Evidence for a change in the retino-hypothalamic projection in the rat following early removal of one eye. *Brain Research* **104** 129–136. (doi:10.1016/0006-8993(76)90652-1)
- Stehle JH, von Gall C, Schomerus C & Korf HW 2001 Of rodents and ungulates and melatonin: creating a uniform code for darkness by different signaling mechanisms. *Journal of Biological Rhythms* **16** 312–325. (doi:10.1177/074873001129002033)
- Stehle JH, von Gall C & Korf HW 2003 Melatonin: a clock-output, a clock-input. *Journal of Neuroendocrinology* **15** 383–389. (doi:10.1046/j.1365-2826.2003.01001.x)
- Stephan FK & Zucker I 1972 Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. *PNAS* **69** 1583–1586. (doi:10.1073/pnas.69.6.1583)
- Stevenson TJ & Prendergast BJ 2015 Photoperiodic time measurement and seasonal immunological plasticity. *Frontiers in Neuroendocrinology* **37** 76–88. (doi:10.1016/j.yfrne.2014.10.002)
- Stirland JA, Johnston JD, Cagampang FR, Morgan PJ, Castro MG, White MR, Davis JR & Loudon AS 2001 Photoperiodic regulation of prolactin gene expression in the Syrian hamster by a pars tuberalis-derived factor.

- Journal of Neuroendocrinology* **13** 147–157. (doi:10.1046/j.1365-2826.2001.00611.x)
- Sun ZS, Albrecht U, Zhuchenko O, Bailey J, Eichele G & Lee CC 1997 RIGUI, a putative mammalian ortholog of the *Drosophila* period gene. *Cell* **90** 1003–1011. (doi:10.1016/S0092-8674(00)80366-9)
- Tamarkin L, Westrom WK, Hamill AI & Goldman BD 1976 Effect of melatonin on the reproductive systems of male and female Syrian hamsters: a diurnal rhythm in sensitivity to melatonin. *Endocrinology* **99** 1534–1541. (doi:10.1210/endo-99-6-1534)
- Tamarkin L, Lefebvre NG, Hollister CW & Goldman BD 1977 Effect of melatonin administered during the night on reproductive function in the Syrian hamster. *Endocrinology* **101** 631–634. (doi:10.1210/endo-101-2-631)
- Teclemariam-Mesbah R, Ter Horst GJ, Postema F, Wortel J & Buijs RM 1999 Anatomical demonstration of the suprachiasmatic nucleus–pineal pathway. *Journal of Comparative Neurology* **406** 171–182. (doi:10.1002/(SICI)1096-9861(19990405)406:2%3C;171::AID-CNE3%3E;3.0.CO;2-U)
- Thomas JM & Hoffman BB 1987 Adenylate cyclase supersensitivity: a general means of cellular adaptation to inhibitory agonists? *Trends in Pharmacological Sciences* **8** 308–311. (doi:10.1016/0165-6147(87)90124-6)
- Torres-Farfan C, Mendez N, Abarzua-Catalan L, Vilches N, Valenzuela GJ & Seron-Ferre M 2011 A circadian clock entrained by melatonin is ticking in the rat fetal adrenal. *Endocrinology* **152** 1891–1900. (doi:10.1210/en.2010-1260)
- Tremblay JJ & Drouin J 1999 Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone β gene transcription. *Molecular and Cellular Biology* **19** 2567–2576.
- Turek FW & Gillette MU 2004 Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. *Sleep Medicine* **5** 523–532. (doi:10.1016/j.sleep.2004.07.009)
- Unfried C, Burbach G, Korf HW & von Gall C 2010 Melatonin receptor 1-dependent gene expression in the mouse pars tuberalis as revealed by cDNA microarray analysis and in situ hybridization. *Journal of Pineal Research* **48** 148–156. (doi:10.1111/j.1600-079X.2009.00738.x)
- Vanecek J 1988a Melatonin binding sites. *Journal of Neurochemistry* **51** 1436–1440. (doi:10.1111/j.1471-4159.1988.tb01108.x)
- Vanecek J 1988b The melatonin receptors in rat ontogenesis. *Neuroendocrinology* **48** 201–203. (doi:10.1159/000125008)
- Vanecek J 1999 Inhibitory effect of melatonin on GnRH-induced LH release. *Reviews of Reproduction* **4** 67–72. (doi:10.1530/ror.0.0040067)
- Vanecek J, Sugden D, Weller J & Klein DC 1985 Atypical synergistic α 1- and β -adrenergic regulation of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in rat pinealocytes. *Endocrinology* **116** 2167–2173. (doi:10.1210/endo-116-6-2167)
- Vriend J 1985 Effects of melatonin and thyroxine replacement on thyrotropin, luteinizing hormone, and prolactin in male hypothyroid hamsters. *Endocrinology* **117** 2402–2407. (doi:10.1210/endo-117-6-2402)
- Warman VL, Dijk DJ, Warman GR, Arendt J & Skene DJ 2003 Phase advancing human circadian rhythms with short wavelength light. *Neuroscience Letters* **342** 37–40. (doi:10.1016/S0304-3940(03)00223-4)
- Weaver DR & Reppert SM 1990 Melatonin receptors are present in the ferret pars tuberalis and pars distalis, but not in brain. *Endocrinology* **127** 2607–2609. (doi:10.1210/endo-127-5-2607)
- Webster JR, Moenter SM, Woodfill CJ & Karsch FJ 1991 Role of the thyroid gland in seasonal reproduction. II. Thyroxine allows a season-specific suppression of gonadotropin secretion in sheep. *Endocrinology* **129** 176–183. (doi:10.1210/endo-129-1-176)
- Witt-Enderby PA, Masana MI & Dubocovich ML 1998 Physiological exposure to melatonin supersensitizes the cyclic adenosine 3',5'-monophosphate-dependent signal transduction cascade in Chinese hamster ovary cells expressing the human mt1 melatonin receptor. *Endocrinology* **139** 3064–3071.
- Wittkowski W, Bockmann J, Kreutz MR & Bockers TM 1999 Cell and molecular biology of the pars tuberalis of the pituitary. *International Review of Cytology* **185** 157–194.
- Wood S & Loudon A 2014 Clocks for all seasons: unwinding the roles and mechanisms of circadian and interval timers in the hypothalamus and pituitary. *Journal of Endocrinology* **222** R39–R59. (doi:10.1530/JOE-14-0141)
- Yasuo S, Watanabe M, Nakao N, Takagi T, Follett BK, Ebihara S & Yoshimura T 2005 The reciprocal switching of two thyroid hormone-activating and -inactivating enzyme genes is involved in the photoperiodic gonadal response of Japanese quail. *Endocrinology* **146** 2551–2554. (doi:10.1210/en.2005-0057)
- Yellon SM & Longo LD 1987 Melatonin rhythms in fetal and maternal circulation during pregnancy in sheep. *American Journal of Physiology* **252** E799–E802.
- Yoshimura T 2013 Thyroid hormone and seasonal regulation of reproduction. *Frontiers in Neuroendocrinology* **34** 157–166. (doi:10.1016/j.yfrne.2013.04.002)
- Yoshimura T, Yasuo S, Watanabe M, Iigo M, Yamamura T, Hirunagi K & Ebihara S 2003 Light-induced hormone conversion of T₄ to T₃ regulates photoperiodic response of gonads in birds. *Nature* **426** 178–181. (doi:10.1038/nature02117)
- Zawilska JB, Skene DJ & Arendt J 2009 Physiology and pharmacology of melatonin in relation to biological rhythms. *Pharmacological Reports* **61** 383–410. (doi:10.1016/S1734-1140(09)70081-7)
- Zemdegs IZ, McMillen IC, Walker DW, Thorburn GD & Nowak R 1988 Diurnal rhythms in plasma melatonin concentrations in the fetal sheep and pregnant ewe during late gestation. *Endocrinology* **123** 284–289. (doi:10.1210/endo-123-1-284)
- Zhdanova Wurtm IV, an RJ, Morabito C, Piotrovska VR & Lynch HJ 1996 Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. *Sleep* **19** 423–431.

Received in final form 29 May 2015

Accepted 17 June 2015

Accepted Preprint published online 22 June 2015